Town & Country Bank & Trust CO dba First Bankers Trust CO Purchases Shares of 2,265 Thermo Fisher Scientific Inc. (NYSE:TMO)

Town & Country Bank & Trust CO dba First Bankers Trust CO acquired a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 2,265 shares of the medical research company's stock, valued at approximately $1,127,000.

A number of other hedge funds and other institutional investors have also modified their holdings of TMO. Semus Wealth Partners LLC lifted its stake in shares of Thermo Fisher Scientific by 4.0% in the fourth quarter. Semus Wealth Partners LLC now owns 471 shares of the medical research company's stock worth $245,000 after acquiring an additional 18 shares during the period. Revolve Wealth Partners LLC increased its holdings in shares of Thermo Fisher Scientific by 4.2% during the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock valued at $255,000 after acquiring an additional 20 shares in the last quarter. Evernest Financial Advisors LLC increased its holdings in shares of Thermo Fisher Scientific by 4.0% during the fourth quarter. Evernest Financial Advisors LLC now owns 521 shares of the medical research company's stock valued at $271,000 after acquiring an additional 20 shares in the last quarter. Proactive Wealth Strategies LLC increased its holdings in shares of Thermo Fisher Scientific by 2.7% during the fourth quarter. Proactive Wealth Strategies LLC now owns 753 shares of the medical research company's stock valued at $392,000 after acquiring an additional 20 shares in the last quarter. Finally, Cassaday & Co Wealth Management LLC boosted its position in shares of Thermo Fisher Scientific by 0.9% during the fourth quarter. Cassaday & Co Wealth Management LLC now owns 2,286 shares of the medical research company's stock valued at $1,189,000 after buying an additional 20 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors.

Thermo Fisher Scientific Stock Down 0.3%

NYSE:TMO traded down $1.34 during trading hours on Friday, reaching $402.41. 2,521,302 shares of the company traded hands, compared to its average volume of 1,878,887. The business's 50-day moving average price is $430.85 and its two-hundred day moving average price is $499.77. The stock has a market capitalization of $151.91 billion, a P/E ratio of 24.34, a P/E/G ratio of 2.99 and a beta of 0.82. Thermo Fisher Scientific Inc. has a 1 year low of $390.50 and a 1 year high of $627.88. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The business had revenue of $10.36 billion during the quarter, compared to analysts' expectations of $10.23 billion. During the same quarter in the previous year, the business earned $5.11 earnings per share. The firm's quarterly revenue was up .2% compared to the same quarter last year. Analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Friday, June 13th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 0.43%. The ex-dividend date of this dividend is Friday, June 13th. Thermo Fisher Scientific's dividend payout ratio is currently 10.09%.

Insider Transactions at Thermo Fisher Scientific

In related news, SVP Michael A. Boxer sold 3,775 shares of Thermo Fisher Scientific stock in a transaction on Monday, March 10th. The stock was sold at an average price of $532.52, for a total value of $2,010,263.00. Following the completion of the sale, the senior vice president now owns 10,816 shares of the company's stock, valued at $5,759,736.32. The trade was a 25.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction on Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the completion of the sale, the executive vice president now directly owns 23,167 shares of the company's stock, valued at $9,960,188.31. The trade was a 1.28% decrease in their position. The disclosure for this sale can be found here. Insiders sold 14,075 shares of company stock worth $7,305,942 over the last quarter. 0.33% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

TMO has been the topic of several research analyst reports. Robert W. Baird cut their price objective on Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating on the stock in a research report on Thursday, April 24th. Argus decreased their price objective on Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating on the stock in a research note on Tuesday, April 29th. Royal Bank of Canada decreased their price objective on Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating on the stock in a research note on Thursday, April 24th. Raymond James reiterated an "outperform" rating and set a $667.00 price objective (up from $650.00) on shares of Thermo Fisher Scientific in a research note on Monday, February 3rd. Finally, Stifel Nicolaus decreased their target price on Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating on the stock in a research note on Thursday, April 24th. Four analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $607.43.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.